Clinical trial NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
Official title: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Colorectal Cancer Metastatic
High Immune Infiltrate
Microsatellite Stable
Keywords: immunotherapy
immune infiltrate
first line
Lead sponsor: Federation Francophone de Cancerologie Digestive
Sponsor class: OTHER
First posted: 2020-02-10
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called CRC with microsatellite stability (MSS). Other CRC, i.e. 15%, are "microsatellite unstable" (MSI) with deficient DNA Mismatch-Repair system (dMMR). These latter are characterised by generation of many neo-antigens, which result in a high anti-tumour immune response and a high peri- and/or intra-tumour lymphocyte infiltration (TIL). Investigators recently showed, with a prospectively validated immune score, that 14% of localised MSS/pMMR CRC are also highly infiltrated by CD3+ lymphocytes. This same immune score has made it possible to measure high lymphocyte infiltration in hepatic metastases, in particular, in patients treated with XELOX/FOLFOX.

Pembrolizumab, an anti-PD1 monoclonal antibody (programmed death-1) is an immune checkpoint inhibitor (ICI) of PD1/PD-L1 axis, recently approved in many cancers. Anti-PD1 antibodies have recently been reported as being very effective in patients with dMMR metastatic CRC (mCRC). In the study by Le DT et al. pMMR mCRC did not seem to benefit from anti-PD1 antibodies. However, it is possible that 20% of pMMR mCRC with a high CD3+ infiltrate in the tumour may be a subgroup of pMMR mCRC sensitive to ICI, as is the case for dMMR mCRC. Lastly, immunogenic cell death induced by chemotherapy, such as oxaliplatin, can increase the efficacy of ICI.

The prognostic value of lymphocyte infiltrate has been demonstrated in CRC by several teams. However, no validated test is used in routine clinical practice. Previously, investigators described an automated and reproducible method for analysis of TIL and investigators validated it for clinical use. Automated tests evaluating TIL are performed on virtual slides and have showed that, out of 1,220 tumours tested, 20% were highly infiltrated by CD3+ T cells. Patients presenting with a pMMR CRC with a high immune infiltrate had a better progression-free survival (HR=0.70; p=0.02). An immunoscore® described by Galon et al. has also a high prognostic value in CRC and is based on CD3+ and CD8+ T cells infiltration in the center and periphery of the tumour. Finally, approximately 14% of tumours with a high immune infiltrate have been found in patients with metastatic CRC.

Investigators formulated the hypothesis that patients with a pMMR CRC with a high immune infiltrate can be sensitive to ICI . Therefore, blocks of resected primary tumour will be collected and analysed prospectively. For each patient, slides containing tumour tissue and adjacent non-tumour tissue will be analysed using two techniques : immunoscore® and TuLIS score.It consist in Immunohistochemistry with CD3 and CD8 staining. Slides will be scanned and analysed by image analysis as previously described . Tumours will then be classified as having a "high" or "low" immune response according to type of lymphocyte infiltrate, which is independent of pre-analytic conditions. Only patients with a high immune response will be eligible for the POCHI trial. Other biomarkers will be analysed like other immune populations or mutational load. If investigators identify an immune score which seems clinically relevant to predict sensitivity to ICI in pMMR mCRC, this will make it possible to plan a randomised phase III trial comparing chemotherapy and anti-angiogenic antibody versus chemotherapy and anti-angiogenic antibody plus pembrolizumab in patients with a pMMR mCRC with a high immune score and/or a hypermutated genotype.

Investigators choose PFS at 10 months as primary endpoint in POCHI trial because it is a surrogate marker of OS. Actually median PFS in first-line setting with a doublet plus a biological agent is range from 8 to 11 months in unresectable mCRC, corresponding to a PFS of 50% at 10 months. The alternative clinical hypothesis to obtain 70% of patients alive and without progression at 10 months is ambitious and currently not achieved with current chemotherapies plus a biological agent. Up until now there is no data concerning survivals outcomes of patients with a MSS mCRC with high immune infiltration score.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* MSS and pMMR metastatic colorectal adenocarcinoma (metachronous or synchronous metastases), histologically proven
* Patients who have had chemotherapy (neo-adjuvant or adjuvant) or radiotherapy (neo-adjuvant or adjuvant) for the treatment of primary tumor or metastatic resected disease R0 can be included if they have a recurrence more than 6 months after the end of this treatment.
* High immune response defined as the immune infiltration scores obtained on the primary tumour (resection of primary tumour containing at least 2 mm of tumour-free margin between the tumour and non-tumour area)
* Unresectable cancer with at least one measurable metastatic target according to RECIST v1.1 criteria
* WHO PS ≤ 1
* Life expectancy ≥ 3 months
* Adequate haematological function: neutrophils ≥ 1,500 /mm3, platelets ≥ 100,000/mm3, Hb \> 9 g/dL
* Adequate liver function: AST/ALT ≤ 5xULN, total bilirubin ≤ 2xULN, alkaline phosphatase. ≤ 5xULN
* Creatinine clearance \> 50 mL/min according to the MDRD formula
* Proteinuria \<2+ (dipstick urinalysis) or ≤1g/24hour
* Patient who is a beneficiary of the social security system
* Information provided to patient and signature of the informed consent form

Exclusion Criteria:

* Active infection requiring intravenous antibiotics at day 1 of cycle 1
* Active or untreated central nervous system metastases
* Another concomitant cancer or history of cancer during the last 5 years, except for carcinoma in situ of the uterine cervix or a basal cell or squamous cell skin carcinoma or any other carcinoma in situ considered as cured
* Previous bone marrow allogenic stem cell transplantation or previous organ transplantation
* History of idiopathic pulmonary fibrosis, medicinal product-related pneumonia or proof of active pneumonia or pneumonitis on a chest CT-scan prior to therapy
* HIV infection, active hepatitis B or C infection, active tuberculosis
* Colorectal cancer with microsatellite instability (dMMR and/or MSI)
* Patient eligible for curative treatment (resection and/or thermal ablation according to the opinion of the local multidisciplinary tumour meeting board)
* Patient with only primary tumour biopsies available or only a sample of a metastasis (no surgical resection of the primary tumour)
* Previous treatment with anti-PD1 or anti-PDL1 or another immunotherapy
* An auto-immune disease which may worsen during treatment with an immune-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo or hyperthyroidism not requiring immunosuppressant therapy are eligible)
* Long-term immunosuppressant therapy (patients requiring corticosteroid therapy are eligible if administration at a dose ≤ 10 mg prednisone equivalent dose per day, administration of steroids by a route of administration resulting in minimal systemic exposure (cutaneous, rectal, ocular or inhalation) is authorised)
* Known severe hypersensitivity to monoclonal antibodies, to one of the medicinal products used or to one of the excipients in the products used or a history of anaphylactic shock or of uncontrolled asthma
* Vaccinations (live vaccine) within 30 days prior to start of treatment
* Dihydropyrimidine Dehydrogenase (DPD) deficiency defined by uracilemy level ≥ 16 ng/mL
* QT/QTc interval \> 450 msec in men and \> 470 msec in women
* One of the following disorders during the 6 months prior to inclusion: myocardial infarction, unstable/severe angina pectoris, coronary artery bypass grafting, NYHA class II, III or IV congestive heart failure, stroke or transient ischaemic attack
* All uncontrolled progressive disorders during the last 6 months: hepatic insufficiency, renal insufficiency, respiratory insufficiency, arterial hypertension
* History of an inflammatory digestive disease, obstruction or sub-obstruction not resolved with symptomatic treatment
* Peptic ulcer disease not healed before the treatment
* Not controlled HTA
* Patient already enrolled in another therapeutic trial with an ongoing investigational drug or whose treatment ended less than 4 weeks before inclusion
* Absence of effective contraception in patients (male and/or female patients) of childbearing potential, a pregnant or breastfeeding woman, women of childbearing potential and who have not had a pregnancy test
* Impossibility to submit to medical follow-up of the trial due to geographic, social or psychological reasons

Primary outcomes:
measure: The rate of patients alive and without progression at 10 months after inclusion
timeFrame: 10 months after inclusion
Secondary outcomes:
measure: Overall survival
timeFrame: Up to 2 years after the end of the treatment
measure: Histological response in case of secondary resection
timeFrame: Up to 2 years after the end of the treatment
Other outcomes:
Locations:
city: Abbeville
country: France
facility: Ch - Centre Hospitalier D'Abbeville
city: Amiens
country: France
facility: Chu - Hôpital Sud
city: Amiens
country: France
facility: Privé - Clinique de L'Europe
city: Angers
country: France
facility: Privé - Ico - Site Paul Papin
city: Annemasse
country: France
facility: Privé - Hôpital Privé Pays de Savoie
city: Antony
country: France
facility: Privé - Hôpital Privé D'Antony
city: Avignon
country: France
facility: Ch - Hôpital Henri Duffaut
city: Avignon
country: France
facility: Prive - Institut Du Cancer Avignon Provence
city: Bayonne CEDEX
country: France
facility: Ch - Centre Hospitalier de La Côte Basque
city: Bayonne
country: France
facility: Privé - Clinique Capio Balharra
city: Beauvais
country: France
facility: Ch - Centre Hospitalier de Beauvais
city: Besançon
country: France
facility: Chu - Hôpital Jean Minjoz
city: Bordeaux CEDEX
country: France
facility: Privé - Polyclinique Bordeaux Nord
city: Bordeaux
country: France
facility: Privé - Cac - Clinique Bergonié
city: Bordeaux
country: France
facility: Privé - Clinique Tivoli
city: Boulogne-sur-Mer
country: France
facility: Ch - Hôpital Duchenne
city: Boulogne
country: France
facility: Chu - Hôpital Ambroise Paré - Service Anatomie Pathologique
city: Brest
country: France
facility: Chu - Hôpital Morvan - Institut de Cancérologie
city: Brest
country: France
facility: Privé - Clinique Pasteur Lanroze Cfro
city: Béziers
country: France
facility: Ch - Centre Hospitalier de Béziers
city: Caen
country: France
facility: Privé - Centre Maurice Tubiana
city: Caen
country: France
facility: Privé - Cac - Centre Francois Baclesse
city: Caen
country: France
facility: Prive - Polyclinique Du Parc Caen
city: Caluire-et-Cuire
country: France
facility: Privé - Infirmerie Protestante de Lyon
city: Challes-les-Eaux
country: France
facility: Privé - Médipole de Savoie
city: Champigny-sur-Marne
country: France
facility: Privé - Hôpital Privé Paul D'Egine
city: Cholet
country: France
facility: Ch - Centre Hospitalier de Cholet
city: Clermont Ferrand
country: France
facility: Chu - Hôpital Estaing
city: Colmar
country: France
facility: Ch - Hôpitaux Civils de Colmar
city: Compiègne CEDEX
country: France
facility: Privé - Clinique Saint Come
city: Coudekerque-Branche
country: France
facility: Privé - Clinique de Flandre
city: Creil
country: France
facility: Ch - Ghpso - Site de Creil
city: Créteil CEDEX
country: France
facility: Chu - Hôpital Henri Mondor
city: Créteil
country: France
facility: Ch - Chic de Créteil
city: Dijon CEDEX
country: France
facility: Chu - Hôpital François Mitterrand
city: Dijon
country: France
facility: Privé - Cac - Centre Georges-Francois Leclerc
city: La Chaussee St Victor
country: France
facility: Privé - Polyclinique de Blois - 3Eme Etage
city: La Roche-sur-Yon
country: France
facility: Ch - Chd Vendée
city: La Rochelle
country: France
facility: CH - GROUPE HOSPITALIER DE La Rochelle RE AUNIS
city: Levallois-Perret
country: France
facility: Privé - Hôpital Franco Britannique
city: Lille
country: France
facility: Privé - Clinique Du Bois
city: Limoges
country: France
facility: Chu - Centre Hospitalier Dupuytren
city: Lorient CEDEX
country: France
facility: Ch - Chbs - Hôpital Du Scorff
city: Lyon
country: France
facility: Privé - Hôpital Jean Mermoz
city: Marseille CEDEX 03
country: France
facility: Privé - Hôpital Europeen
city: Marseille CEDEX 5
country: France
facility: Chu - Hôpital La Timone
city: Marseille
country: France
facility: Privé - Hôpital Saint Joseph
city: Marseille
country: France
facility: Privé - Haliodx
city: Meaux
country: France
facility: Ch - Ghi - Groupe Hospitalier de L'Est Francilien - Site de Meaux
city: Mont-de-Marsan
country: France
facility: Ch - Hôpital Layné
city: Mougins
country: France
facility: Privé - Centre Azureen de Cancerologie
city: Mougins
country: France
facility: Privé - Hôpital Prive Arnault Tzanck
city: Nancy
country: France
facility: Privé - Polyclinique de Gentilly
city: Nîmes
country: France
facility: Chu - Hôpital Carémeau
city: Paris
country: France
facility: Privé - Institut Mutualiste Montsouris
city: Paris
country: France
facility: Chu - Hôpital Europeen Georges Pompidou
city: Paris
country: France
facility: Privé - Groupe Hospitalier Diaconesses Croix Saint Simon
city: Paris
country: France
facility: Chu - Hôpital Saint Antoine
city: Paris
country: France
facility: Chu - Hôpital Saint-Louis
city: Pau CEDEX
country: France
facility: Ch - Centre Hospitalier de Pau
city: Perigueux
country: France
facility: Privé - Polyclinique Francheville
city: Perpignan
country: France
facility: Ch - Centre Hospitalier Saint-Jean
city: Pessac
country: France
facility: Chu - Hôpital Haut Lévêque
city: Pierre-Bénite
country: France
facility: Chu Lyon Sud - Pierre Benite
city: Plérin
country: France
facility: Privé - Centre Cario Hpca
city: Poitiers
country: France
facility: Chu - Centre Hospitalier Universitaire de Poitiers - La Miletrie
city: Quimper
country: France
facility: Ch - Chic de Quimper
city: Reims CEDEX
country: France
facility: Chu - Centre Hospitalier Universitaire Robert Debre
city: Reims
country: France
facility: Privé - Cac - Institut Jean Godinot
city: Rennes CEDEX 9
country: France
facility: Chu - Centre Hospitalier Universitaire Pontchaillou
city: Romans-sur-Isère
country: France
facility: Ch - Hôpital Drome Nord
city: Saint-Grégoire
country: France
facility: Privé - Clinique Saint-Grégoire
city: Saint-Herblain
country: France
facility: Privé - Cac - Ico - Site René Gauducheau
city: Saint-Malo
country: France
facility: Ch - Centre Hospitalier de Saint-Malo
city: Saint-Priest-en-Jarez
country: France
facility: Chu - Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord - Service Hge
city: Saint-Quentin
country: France
facility: Privé - Polyclinique Saint-Claude
city: Sainte-Foy-lès-Lyon
country: France
facility: Privé - Clinique Charcot
city: Strasbourg
country: France
facility: Privé - Clinique Sainte Anne
city: Strasbourg
country: France
facility: Privé - Cac - Paul Strauss / Institut de Cancérologie de Strasbourg Europe
city: Suresnes
country: France
facility: Chu - Hôpital Foch
city: Tarbes
country: France
facility: Privé - Polyclinique de L'Ormeau
city: Toulon
country: France
facility: Ch - Hôpital Sainte Musse
city: Tours CEDEX 9
country: France
facility: Chu - Hôpital Trousseau
city: Valenciennes
country: France
facility: Ch - Centre Hospitalier de Valenciennes
city: Vandœuvre-lès-Nancy
country: France
facility: Privé - Cac - Institut de Cancerologie de Lorraine
city: Vandœuvre-lès-Nancy
country: France
facility: Chu - Hôpital Bradois
city: Villejuif
country: France
facility: Chu - Hôpital Paul Brousse
city: Villejuif
country: France
facility: Privé - Cac - Institut Gustave Roussy
Study officials:
affiliation: CHU Poitiers
name: David TOUGERON, MD,PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carbonnel F, Soularue E, Coutzac C, Chaput N, Mateus C, Lepage P, Robert C. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol. 2017 Apr;39(3):327-331. doi: 10.1007/s00281-016-0613-x. Epub 2017 Jan 16.
citation: Caulet M, Lecomte T, Bouche O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Leger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet. 2016 Nov;55(11):1381-1394. doi: 10.1007/s40262-016-0406-3.
citation: Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
citation: Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245.
citation: Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.
citation: Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001 Feb 1;19(3):843-50. doi: 10.1200/JCO.2001.19.3.843.
citation: Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
citation: Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.
citation: Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
citation: Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9.
citation: Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
citation: Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18.
citation: Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821.
citation: Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragon L, Jacquelot N, Qu B, Ferrere G, Clemenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.
citation: Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37. doi: 10.1038/nrc3066. Epub 2011 May 12.
citation: Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3.
citation: Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001 Nov;313(1-2):139-42. doi: 10.1016/s0009-8981(01)00665-9.
citation: Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.
citation: Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
citation: Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.
citation: Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.